Download App

Log in to access Online Inquiry
Company Overview More
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company’s product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington’s disease, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
CEO: Greene, Barry E.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

SAGE Sage Therapeutics
31.770-0.760-2.34%
Post Mkt Price
31.77000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
-18.9% 1.63B -17.02% 1.74B -17.08% 1.74B 175.7% 1.84B
-Cash and cash equivalents
-80.13% 178.67M -82.29% 294.23M -- -- 129.1% 422.17M
-Short-term investments
30.94% 1.45B 230.26% 1.45B -- -- 193.43% 1.42B
Receivables
-20.06% 19.8M -- 18.51M -- -- -- 24.19M
-Other receivables
-20.06% 19.8M -- 18.51M -- -- -- 24.19M
Prepaid assets
61.18% 37.21M 74.58% 39.84M -- -- 13.17% 34.34M
Total current assets
-18.01% 1.68B -15.16% 1.8B -- -- 172.1% 1.9B
Non current assets
Net PPE
-27.19% 17.6M -39.89% 19.13M -- -- -40.09% 20.34M
-Gross PPE
-20.73% 22.85M -38.06% 24.1M -- -- -37.14% 25.39M
-Accumulated depreciation
-12.81% -5.25M 29.84% -4.97M -- -- 21.59% -5.05M
Other non current assets
25.72% 5.86M 9.16% 5.52M -- -- -11.22% 5.14M
Total non current assets
-18.64% 23.46M -33.17% 24.65M -- -- -35.88% 25.48M
Total assets
-18.02% 1.71B -15.47% 1.83B -15.47% 1.83B 160.91% 1.93B
Liabilities
Current liabilities
Payables
117.02% 7.13M 183.12% 10.45M -- -- 10.35% 4.73M
-accounts payable
117.02% 7.13M 183.12% 10.45M -- -- 10.35% 4.73M
Current accrued expenses
22.62% 63.05M 22.65% 67.28M -- -- 42.86% 66.8M
Current debt and capital lease obligation
2.97% 7.52M -13.78% 7.47M -- -- -13.99% 7.41M
-Current capital lease obligation
2.97% 7.52M -13.78% 7.47M -- -- -13.99% 7.41M
Current liabilities
25.31% 77.7M 26.77% 85.19M -- -- 32.31% 78.94M
Non current liabilities
Long term debt and capital lease obligation
-39.03% 9.4M -43.6% 10.96M -- -- -40.76% 12.48M
-Long term capital lease obligation
-39.03% 9.4M -43.6% 10.96M -- -- -40.76% 12.48M
Other non current liabilities
-- 102K -62.96% 100K -- -- -67.09% 103K
Total non current liabilities
-38.37% 9.5M -43.86% 11.06M -- -- -41.15% 12.58M
Total liabilities
12.63% 87.2M 10.75% 96.26M 10.75% 96.26M 12.93% 91.53M
Shareholders'equity
Share capital
0% 6K 0% 6K -- -- 20% 6K
-common stock
0% 6K 0% 6K -- -- 20% 6K
-Preferred stock
-- 0 -- 0 -- -- -- 0
Retained earnings
-42.72% -1.62B -44.13% -1.5B -- -- 31.89% -1.37B
Paid-in capital
3.52% 3.25B 3.78% 3.23B -- -- 20.14% 3.21B
Less: Treasury stock
0% 400K 0% 400K -- -- 0% 400K
Gains losses not affecting retained earnings
-4646.19% -11.2M -740.96% -2.66M -- -- -132.35% -306K
Total stockholders'equity
-19.21% 1.62B -16.57% 1.73B -16.57% 1.73B 179.15% 1.84B
Total equity
-19.21% 1.62B -16.57% 1.73B -16.57% 1.73B 179.15% 1.84B
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%